Advertisement
Skip to Content

Allena Pharmaceuticals Inc ALNAQ Stock Quote

PINX: ALNAQ

Last close prices updated as of Jan 26, 2023, 12:49 PM EST | USD
  • Last Close 0.004
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  0.55
  • Market Cap 488,332.9040
  • Volume / Avg 32,798.0 /  580,874.7
  • Price / Sales
  • Price / Book 0.13
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ALNAQ

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ALNAQ

Company Profile ALNAQ

Business Description

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Contact
One Newton Executive Park, Suite 202
Newton, MA, 02462
Industry Biotechnology
Employees 21

FAQs for Allena Pharmaceuticals Inc Stock

No. ALNAQ does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ALNAQ’s market cap is 488,332.90.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ALNAQ’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ALNAQ’s historical performance against its industry peers and the overall market.